Medical devices, healthcare technology and the business of care
PMA approval · P230016

MAGE-A4 IHC 1F9 pharmDx

Agilent Technologies, Inc. · Decision date Aug 1, 2024

MEDTECHLEDGER EXPLANATIONP230016

What did the FDA approve?

The FDA database lists an approval decision dated 2024-08-01 for MAGE-A4 IHC 1F9 pharmDx, submitted by Agilent Technologies, Inc. under product code SBL. The supplied record identifies no supplement type or reason, so it does not establish this as a supplement to an earlier PMA; the decision is described only at the level of the device record.

The statement describes a qualitative immunohistochemical assay using monoclonal mouse anti-MAGE-A4, Clone OTI1F9, on the EnVision FLEX visualization system with Autostainer Link 48, for detecting MAGE-A4 protein in formalin-fixed, paraffin-embedded synovial sarcoma tissue. Expression is scored with the MAGE-A4 Tumor Intensity Proportion Score, counting viable tumor cells with nuclear and/or cytoplasmic staining at intensity ? 2+, with a positive specimen at ? 75%. The stated indication is aid in identifying adult synovial sarcoma patients for whom TECELRA (afamitresgene autoleucel) is being considered.

FDA approval order statement

MAGE-A4 IHC 1F9 pharmDx is a qualitative immunohistochemical (IHC) assay using monoclonal mouse anti-MAGE-A4, Clone OTI1F9, intended for use in the detection of MAGE-A4 protein in formalin-fixed, paraffin-embedded (FFPE) synovial sarcoma tissues using the EnVision FLEX visualization system on Autostainer Link 48. MAGE-A4 protein expression in synovial sarcoma is determined by using the MAGE-A4 Tumor Intensity Proportion Score (TIPS), which is the overall percentage of viable tumor cells showing MAGE-A4 nuclear and/or cytoplasmic staining at staining intensity ? 2+. The specimen should be considered positive if MAGE-A4 TIPS (? 2+) is ? 75%.MAGE-A4 IHC 1F9 pharmDx is indicated as an aid in identifying adult patients with synovial sarcoma for whom TECELRA (afamitresgene autoleucel), a MAGE-A4 directed genetically modified autologous T- cell immunotherapy is being considered.
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
Aug 1, 2024

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230016
Regulatory pathway
Premarket approval application
Product code
SBL
Decision code
APPR
Decision date
Aug 1, 2024
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Immunohistochemistry Assay, Antibody, Melanoma-associated antigen A4.

Product code
SBL
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P230016 received

    Application receipt date recorded by FDA.

  2. P230016 · FDA decision

    APPR

  3. P230016/S005 · Related supplement

    MAGE-A4 IHC 1F9 pharmDx

  4. P230016/S003 · Related supplement

    MAGE-A4 IHC 1F9 pharmDx

  5. P230016/S004 · Related supplement

    MAGE-A4 IHC 1F9 pharmDx

Timeline entries are records held by MedtechLedger for P230016. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230016

Product / regulatory recordCompanyPathwayDecision dateSource
Agilent Technologies, Inc.PMA supplementSep 11, 2026FDA
Agilent Technologies, Inc.PMA supplementSep 15, 2026FDA
Agilent Technologies, Inc.PMA supplementSep 21, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Agilent Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6392 Via Real, Carpinteria, CA, 93013

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records